Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 08, 2018 16:01 ET | Source: MyoKardia, Inc.

MyoKardia Reports First Quarter 2018 Financial Results

Company to Host Conference Call and Webcast Today at 4:30 p.m. ET (1:30 p.m. PT) SOUTH SAN FRANCISCO, Calif., May 08, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage...
May 03, 2018 16:01 ET | Source: MyoKardia, Inc.

MyoKardia to Report First Quarter 2018 Financial Results on Tuesday, May 8, 2018

SOUTH SAN FRANCISCO, Calif., May 03, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of...
April 04, 2018 08:30 ET | Source: MyoKardia, Inc.

MyoKardia Announces Appointment of Taylor C. Harris as Chief Financial Officer

SOUTH SAN FRANCISCO, Calif., April 04, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment...
April 02, 2018 08:30 ET | Source: MyoKardia, Inc.

MyoKardia Begins Dosing in Phase 2 MAVERICK-HCM Clinical Trial of Mavacamten in Symptomatic Non-obstructive Hypertrophic Cardiomyopathy Patients

SOUTH SAN FRANCISCO, Calif., April 02, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment...
March 08, 2018 16:03 ET | Source: MyoKardia, Inc.

MyoKardia Reports Fourth Quarter and Full Year 2017 Financial Results

Announced Achievement of Primary Endpoint and Additional Key Data from Low-Dose Mavacamten Cohort of PIONEER-HCM Phase 2 Study in Symptomatic, Obstructive Hypertrophic Cardiomyopathy Company to Host...
March 08, 2018 16:02 ET | Source: MyoKardia, Inc.

MyoKardia Announces Positive Results from Low-Dose Cohort of Phase 2 PIONEER-HCM Study of Mavacamten in Symptomatic, Obstructive Hypertrophic Cardiomyopathy Patients

Met Primary Endpoint and Key Secondary Endpoints with Statistical Significance Study Results Inform Phase 3 EXPLORER-HCM Dosing; First Patient Planned for Q2 2018 Conference Call Today...
March 06, 2018 08:00 ET | Source: MyoKardia, Inc.

MyoKardia to Present at the Cowen and Company 38th Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment...
March 01, 2018 16:30 ET | Source: MyoKardia, Inc.

MyoKardia to Report Fourth Quarter and Full Year 2017 Financial Results on Thursday, March 8, 2018

SOUTH SAN FRANCISCO, Calif., March 01, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment...
February 14, 2018 16:30 ET | Source: MyoKardia, Inc.

MyoKardia to Present at the RBC Capital Markets’ 2018 Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Feb. 14, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of...
February 14, 2018 08:30 ET | Source: MyoKardia, Inc.

MyoKardia Begins Patient Dosing in Phase 1b Clinical Study of MYK-491 in Dilated Cardiomyopathy Patients

SOUTH SAN FRANCISCO, Calif., Feb. 14, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right